The European Technology Platform on Nanomedicine
White PaperNanomedicine Contribution
to Horizon 2020
Identification of European Nanomedicine Actors
ETP NanomedicineApply for Membership
- Featured News
The European Foundation for Clinical Nanomedicine (CLINAM), the European Technology Platform on Nanomedicine (ETPN) and the European Society for Nanomedicine invite you to participate in CLINAM 2014, the 7th European Summit for Clinical Nanomedicine and Targeted Medicine on June 23-25, 2014 in Basel (Switzerland).
Bionest Partners recently made public in a dedicated press conference their 2014 nanomedicine exhaustive study conducted for the French Drug Syndicate LEEM (Pharmaceutical Drug Industry Association) and as an update of their 2008 report.
The ETPN released the 1st Newsletter in 2014 with focus on Horizon 2020
The ETPN continues its collaboration and series of nanomedicine articles with the International Innovation magasine, with an overview of nanomedicine based solutions in ophthalmology and their hopes for the future of this field.
Organised in collaboration with The British Society for Nanomedicine (BSNM), the exciting Nanomedicine 2014 programme will provide insight across a number of emerging nanotechnologies that span from treatment to diagnosis.
The 5th International Congress - BioNanoMed 2014 – is the exclusive Know-How-Transfer meeting for scientists, researchers, engineers and practitioners from Natural Science, Medical Science and Engineering Subjects throughout the world and dedicated to Nanotechnology, Medicine and Biology. The Call for Papers is now open till 17 December 2013.
The 2014 Conference will focus on the emerging field of neuronanomedicine. The ASNM Annual meeting will provide a venue to catalyze interactions among investigators through sharing ideas, research discoveries, and challenges towards advancing the field of nanomedicine
When Medicinal Chemistry meets Nanomedicines: Molecular Aspects of Targeting Activation and Delivery of Drugs
This Joint Meeting between French Medicinal Chemistry Society and French Society for Nanomedecine will focus on: (i) molecular aspects of targeting-activation and delivery of drugs; (ii) preclinical and clinical considerations of the DDS and conjugates of third generation, present status and perspectives.